In a first part of our study we analysed urine samples (stored in liquid nitrogen) of multiple myeloma patients, treated with arsenic, in a very short time. Samples stored in such a way do not contain (almost) any trivalent arsenic methabolites. We also found out that some compounds (eg. reduced glutathion, cysteine, metallothioneine and ferritine) in blood samples can simultaneously bind arsenite and ireversibly attach to a chromatographical column.
COBISS.SI-ID: 21294375
Arsenite toxicity triggers autophagy in cancer cells, and final stages of the process involve executive caspases, suggesting an interplay between autophagic and apoptotic pathways. We evaluated the contribution of cathepsins (Cat) L and B, that are involved both in autophagy and apoptosis and are upregulated in glioblastomas. In human glioblastoma cells arsenite toxicity is associated with inhibition of CatB and CatL. The latter points on a synergy that could be used in clinical treatment to lower the therapeutic dose, thus avoiding toxic side effects of arsenite in glioblastoma management.
COBISS.SI-ID: 2213967
As the ATO therapeutic doses are rather high, and As-Se interactions well-known, we supposed that As interferences with Se metabolism - compromised antioxidative system? - are unavoidable during such treatment. In this study we followed total plasma concentrations of Se and As, their binding to selenoprotein P (Sel-P) and total urine Se and As concentrations in APL and multiple myeloma patients during As2O3 therapy (iv infusion, 0.15 mg/kg body weight per day or 0.25 mg/kg body wight twice per week ). Relevant fall in serum (together with SelP) and urine Se was observed in most cases.
COBISS.SI-ID: 23810599
This work summarises main findings on appearance of chromosomal abberations at Slovene multiple myeloma patients. Their coappearance was studied as well. Article also gives the importance of their routine examination at regular diagnostic meetings with DP patients.
COBISS.SI-ID: 27571417